MarketCap
Facebook
X
TelegramGeschäftsbericht 2020
hinzugefügt 16.12.2023
Burford Capital Limited Gesamtverbindlichkeiten 2011-2025 | BUR
Gesamtverbindlichkeiten Jährlich Burford Capital Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.45 B | 1.54 B | 956 M | 701 M | 372 M | 160 M | 151 M | 24.6 M | 12.9 M | 12.6 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.54 B | 12.6 M | 538 M |
Gesamtverbindlichkeiten Vierteljährlich Burford Capital Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 1.45 B | - | - | - | 1.54 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.54 B | 1.45 B | 1.5 B |
Gesamtverbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtverbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
38.4 M | $ 4.72 | 0.96 % | $ 783 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
64.8 M | $ 3.32 | -1.19 % | $ 257 M | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
845 M | $ 25.26 | -2.47 % | $ 1.22 B | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
243 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
90.7 M | - | - | $ 1.01 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
1.29 B | $ 209.93 | -0.11 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 1.31 | -1.88 % | $ 7.14 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.4 | -0.71 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
63.2 B | $ 89.77 | -0.57 % | $ 96.9 B | Britain |
 |
Anika Therapeutics
ANIK
|
42.3 M | $ 9.59 | 1.05 % | $ 141 M | USA |
 |
Brickell Biotech
BBI
|
6.5 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.59 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
84 M | - | -7.31 % | $ 87 M | USA |
 |
Biogen
BIIB
|
11.3 B | $ 174.05 | 0.9 % | $ 25.3 B | USA |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.33 | 2.08 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
110 M | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
34.3 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
Benitec Biopharma
BNTC
|
2.3 M | $ 12.26 | -5.4 % | $ 505 M | USA |
 |
BioNTech SE
BNTX
|
3.12 B | $ 94.78 | -1.28 % | $ 27.2 B |  Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
22.2 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
2.15 B | $ 570.12 | -1.88 % | $ 43.2 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 0.28 | -2.76 % | $ 609 M | Israel |
 |
Catalyst Biosciences
CBIO
|
38.1 M | $ 14.66 | -4.25 % | $ 965 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
5.68 M | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
752 M | - | -7.23 % | $ 13 M | USA |
 |
BioVie
BIVI
|
2.55 M | $ 1.47 | -2.55 % | $ 2.17 M | USA |
 |
Cortexyme
CRTX
|
82.8 M | - | -1.05 % | $ 67.1 M | USA |
 |
Celldex Therapeutics
CLDX
|
45.3 M | $ 27.54 | -1.43 % | $ 1.77 M | USA |
 |
Cellectar Biosciences
CLRB
|
25.9 M | $ 3.61 | -4.5 % | $ 44.1 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
123 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.76 B | $ 11.3 | -1.22 % | $ 731 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
31.8 M | - | -5.68 % | $ 8.28 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Enochian Biosciences
ENOB
|
29.6 M | - | - | $ 40.5 M | USA |
 |
Epizyme
EPZM
|
289 M | - | - | $ 249 M | USA |
 |
Cerus Corporation
CERS
|
144 M | $ 2.15 | -0.23 % | $ 397 M | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |